Targeting Hyaluronan in Vascular Diseases with
Special Reference to Diabetic Macroangiopathy

Annele Sainio; Hannu Järveläinen

doi:10.26717/BJSTR.2018.12.002269

Mini ReviewOpen Access

Targeting Hyaluronan in Vascular Diseases with Special Reference to Diabetic Macroangiopathy

Volume 12 - Issue 3

**Annele Sainio*¹ and Hannu Järveläinen^1,2**

Author Information Open or Close
- ¹Institute of Biomedicine, University of Turku, Turku, Finland
- ²Department of Internal Medicine, Satakunta Central Hospital, Pori, University of Turku, Turku, Finland

Received: December 17, 2018; Published: January 02, 2019

DOI: 10.26717/BJSTR.2018.12.002509

Full Text PDF

To view the Full Article Peer-reviewed Article PDF

Abstract

Vascular Extracellular Matrix (ECM) is a dynamic structure, which regulates blood vessel morphogenesis, provides organizational stability, and modulates various aspects of cell behavior [1]. Hyaluronan (HA) represents one of the most abundant macromolecules of the vascular wall. One of its main functions is to maintain blood vessel integrity [2]. Thus, any alteration in the metabolism of HA can predispose to the development and progression of atherosclerotic vascular diseases including diabetic macroangiopathy [3,4].

Abbreviations : CD44: Cluster Determinant 44; ECM: Extracellular Matrix; GlcNac: N-Acetylglucosamine; GlcUA: D-Glucuronic Acid; HA: Hyaluronan; HAS1-3; Hyaluronan Synthases 1-3; HMW: High Molecular Weight; HYALs; Hyaluronidases; IL-1β: Interleukin-1β; LMW: Low Molecular Weight; 4-MU: 4-Methylumbelliferone; ROS: Reactive Oxygen Species; TLRs: Toll Like Receptors; V(SMC) Vascular (Smooth Muscle Cell)

Introduction| Targeting HA in Atherosclerotic Vascular Diseases| Conclusion| References|